BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1173 related articles for article (PubMed ID: 30666022)

  • 1. Factors affecting the accuracy of
    Kutluturk K; Simsek A; Comak A; Gonultas F; Unal B; Kekilli E
    Niger J Clin Pract; 2019 Jan; 22(1):63-68. PubMed ID: 30666022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.
    Choi WH; Yoo IR; O JH; Kim SH; Chung SK
    Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
    BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer.
    Kitajima K; Fukushima K; Miyoshi Y; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Maruyama K; Yamano T; Doi H; Yamakado K; Hirota S; Hirota S
    Jpn J Radiol; 2016 Mar; 34(3):220-8. PubMed ID: 26715510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
    Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
    Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Kuwano H
    Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
    Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective comparative study of ultrasonography, contrast-enhanced MRI and 18F-FDG PET/CT for preoperative detection of axillary lymph node metastasis in breast cancer patients.
    Guney IB; Dalci K; Teke ZT; Kucuker KA
    Ann Ital Chir; 2020; 91():458-464. PubMed ID: 32213685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.
    Kim J; Lee J; Chang E; Kim S; Suh K; Sul J; Song I; Kim Y; Lee C
    World J Surg; 2009 May; 33(5):943-9. PubMed ID: 19259728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Axillary SUV
    Karabacak U; Turkan H; Coskun G; Mollaoglu MC; Hasbek Z; Karadayi K
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):374-379. PubMed ID: 37190706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-fluoro-2-deoxy-D-glucose positron emission tomography versus conventional imaging for the diagnosis of breast cancer and lymph node metastases.
    Shao M; Zi J; Wen G
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S661-S666. PubMed ID: 30249884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET for axillary lymph node staging in primary breast cancer.
    Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
    Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
    Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value, sensitivity, specificity, and accuracy of PET CT in the evaluation of axillary metastases in breast cancer.
    Cetindag Ö; Avsar G; Hakseven M; Deryol R; Ertekin SÇ; Karasoy D; Eroglu A; Bayar S
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10008-10015. PubMed ID: 37916371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of 18F-FDG PET/CT and ultrasonography in the diagnosis of breast cancer and axillary lymph node metastasis.
    He X; Sun L; Huo Y; Shao M; Ma C
    Q J Nucl Med Mol Imaging; 2017 Dec; 61(4):429-437. PubMed ID: 25823388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.
    Heusner TA; Kuemmel S; Hahn S; Koeninger A; Otterbach F; Hamami ME; Kimmig KR; Forsting M; Bockisch A; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1543-50. PubMed ID: 19415270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
    Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
    Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant results in
    Parisse-Di Martino S; Faure C; Mognetti T
    Cancer Treat Res Commun; 2021; 27():100344. PubMed ID: 33636590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.